Systemic therapy for advanced pancreatic cancer

Expert Review of Anticancer Therapy

Volumn 2, Issue 4, 2002, Pages 426-436

  El Rayes, Basil F ^a   Philip, Philip A ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Gemcitabine; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BATIMASTAT; CAPECITABINE; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXATECAN; FLUOROURACIL; FOLIC ACID ANTAGONIST; GEMCITABINE; INDOMETACIN; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MITOMYCIN C; NITROSOUREA; OXALIPLATIN; PACLITAXEL; PEMETREXED; PROTEASOME INHIBITOR; RUBITECAN; STREPTOZOCIN; SULINDAC; TANOMASTAT; TAXANE DERIVATIVE; UNINDEXED DRUG; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC ANTIMETABOLITE; CYCLOOXYGENASE 2; DEOXYCYTIDINE; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

ADVANCED CANCER; ANEMIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG RESPONSE; DRUG TARGETING; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PANCREAS CANCER; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; CELL CYCLE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; METABOLISM; ONCOGENE RAS; PANCREAS TUMOR; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL CYCLE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DEOXYCYTIDINE; DNA TOPOISOMERASES, TYPE I; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FLUOROURACIL; GENES, RAS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PANCREATIC NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SIGNAL TRANSDUCTION;

EID: 0036684317     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.4.426     Document Type: Review

References (78)

1. Cancer statistics, 2002
2. Cancer of the pancreas
3. Prognostic indicators for survival after resection of pancreatic adenocarcinoma
4. Pancreatic cancer
5. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin and mitomycin
6. Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: A randomized trial
7. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors
8. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
9. Phase II study of gemcitabine in patients with advanced pancreatic cancer
10. A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
11. Randomized Phase II trail of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic Adenocarcinoma
12. Phase II study of oral capecitabine in patients with advanced pancreatic cancer
13. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study
14. A study of 9-nitrocamptothecin (RFS-20000) in patients with advanced pancreatic cancer
15. A Phase II study of rubitecan (9NC) in patients with refractory pancreatic cancer
16. Final results of a Phase II study of DX-8951f (Extacen Mesylate, DX) in advanced pancreatic cancer
17. A Phase II study: Docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma
18. Phase II study of docetaxel in patients with metastatic pancreatic cancer: A Japanese co-operative study
19. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin and mitomycin (FAM) with 5-fluorouracil, streptozotocin and mitomycin (FSM)
20. Phase II studies of drug combinations in advanced pancreatic carcinoma: Fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil
21. Efficacy of 5-FU+cisplatin (fup) compared to bolus 5-fu (fu) in advanced pancreatic carcinoma (apc): A randomized trial from the French Anticancer Centers Digestive Group (FNLCCDG). St. Cloud; CHU, Besançon, France
22. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer
23. A Phase III study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): An Eastern Co-operative Oncology Group (ECOG) trial
24. Gemcitabine: Preclinical pharmacology and mechanisms of action
25. Gemcitabin and cisplatin in the treatment of advanced or metastatic pancreatic cancer
26. Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer
27. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized Phase III study of the Gruppo Oncologia dell'Italia Meridionale
28. Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines
29. A Gemcitabine combined with Oxaliplatin in advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter Phase II study
30. Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas
31. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A Phase II study of the Greek Co-operative Group for Pancreatic Cancer
32. Front-line treatment with gemcitabine in combination with Irinotecan: Preliminary results of a multicenter Phase II study
33. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer
34. Clinical outcomes in patients with advanced pancreatic cancer treated with pemetrexed/gemcitabine
35. Weekly chemotherapy with Irinotecan plus taxanes in advanced pancreatic cancer
36. Phase II study of gemcitabine, cisplatin and infusional 5-FU in patients with metastatic pancreatic cancer
37. Definitive results of a Phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil and gemcitabine in stage IV pancreatic adenocarcinoma
38. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma
39. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer
40. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial
41. A comparison between gemcitabine ant the matrix metalloproteinase inhibitor (MMP) BAY 12-9566 in patients with advanced pancreatic cancer
42. Intracellular unesterified arachidonic acid signals apoptosis
43. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
44. COX-2, iNOS and p53 as play-makers of tumor angiogenesis
45. Cyclooxygenase-2 expression is upregulated in human pancreatic cancer
46. The role of cyclooxygenases in inflammation, cancer and development
47. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal antiinflammatory drugs
48. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha
49. Growth factors and their receptors in pancreatic cancer
50. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness
51. Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum
52. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma
53. The nuclear factor-k B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells
54. Transforming activity and mitosis-related expression of the AKT2 oncogene: Evidence suggesting a link between cell cycle regulation and oncogenesis
55. Antitumor efficacy of a novel class of nonthiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol and gemcitabine
56. A Phase II study of the farnesyl transferase inhibitor R115777 in pancreatic cancer. A Southwestern Oncology Group (SWOG) study
57. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice
58. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by anti-angiogenic mechanisms
59. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients advanced pancreatic cancer
60. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
61. Inhibition of ERBB family receptors by CI-1033 enhances the cytotoxicity of gemcitabine via modulation of akt and MAPKs
62. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells
63. Cell cycle-mediated drug resistance: An emerging concept in cancer therapy
64. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with downregulation of ribonucleotide reductase M2 subunit
65. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning
66. The odyssey of angiogenin: A protein that induces blood vessel growth
67. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma
68. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo
69. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin
70. A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
71. Preclinical antitumor activity of CI-994
72. Randomized, double-blinded, placebo control Phase 2 study of the histone deacetylase inhibitor CI-994 plus gemcitabine versus placebo plus gemcitabine in the treatment of patients with advanced pancreatic cancer
73. Phage display panning of irofulven identifies potential intracellular targets
74. Irofluven-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases
75. Phase I clinical and Pharmacokinetic: Trials of irofulven
76. Irofulven monotherapy: Impressive Phase I and II clinical antitumor activity in heavily treated patients
77. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy
78. Phase I and Pharmacological study of weekly adminstration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors